Selank dosage is one of the most frequently searched topics related to this peptide. Unlike conventional drugs, Selank currently lacks widely accepted dosing guidelines developed from large international clinical trials. Most of the available information comes from Russian clinical trials, experimental studies, animal models, and observational protocols used in the research setting.
Since dosage can vary depending on the study's purpose, route of administration, and individual body response, it's worth understanding what dosage ranges have been used in the available scientific literature. You can find more information about the properties and mechanisms of action of this peptide in our main guide regarding Selank.
What doses of Selank were used in studies?
Selank has primarily been studied as a peptide administered intranasally, and this is the most commonly described route of administration in both scientific research and clinical practice.
Human studies on anxiety, stress adaptation, cognitive function, and neuropsychiatric effects have primarily used intranasal administration, rather than injectable forms [1–4].
In animal studies, a wide range of doses was used depending on the experimental model. For example, long-term studies using the Selank analog TP-7 at a dose of 0.3 mg/kg per day showed a significant reduction in anxiety-related behaviors after four weeks of administration [5].
Laboratory studies analyzing GABA receptor modulation, BDNF regulation, antiviral activity, immune response, and gene expression have also used various dosing regimens that cannot be directly translated to humans [6–9].
Typical Selank Dosage Ranges Discussed in Clinical Practice
Based on published literature and commonly discussed peptide protocols, Selank is typically used in microgram quantities.
The most common daily ranges include:
| Experience level | Typical daily range |
|---|---|
| Low dose | 250–500 mcg per day |
| Moderate dose | 500–1000 mcg daily |
| Higher dose | 1000–2000 mcg per day |
When administered nasally, doses are often divided into several applications throughout the day.
It should be emphasized that the given ranges reflect clinical practices and observational peptide protocols, not internationally approved therapeutic guidelines.
Selank Dosage for Anxiety
Many people looking for information on Selank dosage are interested in its potential impact on anxiety and stress management. Research suggests that Selank may support emotional balance through several biological mechanisms.
Laboratory studies indicate that Selank acts as a positive allosteric modulator of GABA receptors, supporting proper inhibitory neurotransmission in the brain [1]. Additionally, it has been shown to inhibit enzymes responsible for the breakdown of enkephalins – natural neuropeptides involved in mood regulation and stress adaptation [10].
Studies have also shown an impact on neurotransmitter systems related to emotion regulation and on neurotrophic factors, such as BDNF (brain-derived neurotrophic factor), which plays an important role in neuroplasticity and neuronal resilience [1,3,7].
Unlike benzodiazepines, Selank does not appear to act by directly activating receptors and may not produce an immediate sedative effect. Its effects may develop gradually through the modulation of multiple regulatory systems.
Selank Dosage for Cognitive Function Support
Research on the effects of Selank on cognitive functions suggests that the peptide may interact with processes related to memory, learning, concentration, neuroplasticity, and cognitive functioning under stress conditions [3,7].
For this reason, Selank is often compared to Semax. Although both peptides stem from a Russian peptide research program, their primary areas of scientific focus differ. Semax is more commonly studied for its effects on cognitive enhancement and neuroprotection, while Selank is primarily associated with anxiety regulation, emotional balance, and stress resistance [3].
Selank 10 mg - How Long Does a Vial Last?
One common question is how long a vial containing 10 mg of Selank can last. The answer depends entirely on the amount used each day.
For example:
| Daily amount | Estimated time of use of a 10 mg vial |
|---|---|
| 250 mcg/day | About 40 days |
| 500 mcg/day | About 20 days |
| 1000 mcg/day | About 10 days |
| 2000 mcg/day | About 5 days |
Actual protocols may vary significantly and should be determined by qualified professionals, where applicable.
Selank intranasally or subcutaneously?
Nasal Catheter
Most published studies on Selank involve intranasal administration, as this was the primary route of administration used in clinical and experimental studies [2,7].
Researchers point to several potential advantages of this method, including its non-invasiveness, rapid absorption through the nasal mucosa, and broad use in historical research programs on Selank.
Subcutaneous injection
Protocols using subcutaneous administration of Selank are often discussed in peptide-interested communities, however, there are significantly fewer scientific publications available compared to intranasal administration.
Due to the limited number of clinical trials involving humans, evidence-based recommendations for the injectable dosage of Selank have not yet been established.
How Often is Selank Used?
Research protocols varied significantly depending on the study design and the objective being analyzed.
Some mechanistic studies have analyzed single dosing [1]. Anxiety-related studies often utilized daily dosing [5], whereas other behavioral experiments involved multi-week dosing regimens [5]. Additional neurobiological studies on BDNF regulation and neurotransmitter activity also employed different intranasal administration schedules [7].
Since large, long-term clinical studies are still lacking, the optimal frequency of use remains undetermined.
Does a Higher Dose of Selank Mean Better Effects?
Currently available data do not indicate that higher doses automatically lead to better outcomes.
Research suggests that Selank affects multiple regulatory systems, including GABA signaling, endogenous opioid pathways, neurotrophic factors, neurotransmitter regulation, and immune response [1,7,10]. These systems often exhibit nonlinear biological responses, meaning that increasing the dose beyond a certain level may not proportionally increase the observed effects.
For this reason, researchers emphasize the importance of an individual approach rather than assuming that more automatically means more benefits.
Key Information
Selank is most often studied as a nasal peptide and analyzed primarily for its potential effects on anxiety reduction, stress resilience, cognitive function support, emotional regulation, and the functioning of the nervous system.
Currently, there are no widely accepted dosing guidelines. The most commonly discussed daily ranges are between 250 and 2000 mcg; however, these values are based primarily on clinical practice and observational research protocols, rather than internationally approved recommendations.
Most mechanistic and clinical data comes from Russian research programs and smaller studies. Further large-scale clinical trials are needed to determine optimal dosing strategies, long-term safety, and efficacy.
Disclaimer
The content presented in this article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, treatment, or dosing recommendations. Selank is not approved for all uses in many countries, and standardized dosing guidelines have not been established based on large international clinical trials. Any decisions regarding peptide therapy should be discussed with a qualified healthcare professional.
For research purposes only: Selank products offered by Semax Polska are intended solely for laboratory and scientific research. They are not intended for human consumption or for use in the diagnosis, treatment, prevention, or alleviation of any disease. Researchers should use these materials in accordance with applicable laws, regulations, and standards for conducting scientific research.
References
[1] Vyunova, T. V., Andreeva, L. A., Shevchenko, K. V., & Myasoedov, N. F. (2018). Peptide-based anxiolytics: The molecular aspects of heptapeptide Selank's biological activity. Protein and Peptide Letters, 25(10), 914–923. https://doi.org/10.2174/0929866525666180925144642
[2] Prakhye, I., et al. (2017). Behavioral Neurology review discussing Selank's neurobiological and clinical effects. Behavioral Neurology. https://onlinelibrary.wiley.com/doi/full/10.1155/2017/5091027
[3] PubChem. (2026). Selank Compound Summary. National Center for Biotechnology Information. https://pubchem.ncbi.nlm.nih.gov/compound/Selank
[4] Letters to the Journal of Experimental and Clinical Pharmacology. Clinical and pharmacological investigations involving Selank. https://www.pismin.com/10.1134/S1062359019040071
[5] Czabak-Garbacz, R., Cygan, B., Wolański, Ł., & Kozlovsky, I. (2006). Influence of long-term treatment with tuftsin analogue TP-7 on anxiety-phobic states and body weight. Pharmacological Reports, 58(4), 562–567. PMID: 16963804
[6] Kost, N. V., Sokolov, O. Y., Zozulya, S. A., & Myasoedov, N. F. (2025). Combined action of benzodiazepine tranquilizers and peptide anxiolytic Selank in BALB/c mice. Neurochemical Journal, 19, 743–748. https://doi.org/10.1134/S1819712425700783
[7] Levitskaya, N. G., Andreeva, L. A., Nagaev, I. Y., Mezentseva, M. V., Shapoval, I. M., Podchernyaeva, R. Y., Shcherbenko, V. E., Potapova, L. A., Russu, L. I., Ershov, F. I., & Myasoedov, N. F. (2010). Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Doklady Biological Sciences, 431, 79–82. Available from: https://www.researchgate.net/profile/Natalia-Levitskaya/publication/23306196
[8] Andreeva, L. A., Nagaev, I. Y., Mezentseva, M. V., Shapoval, I. M., Podchernyaeva, R. Y., Shcherbenko, V. E., Potapova, L. A., Russu, L. I., Ershov, F. I., & Myasoedov, N. F. (2010). Antiviral properties of structural fragments of the peptide Selank. Doklady Biological Sciences, 431(1), 79–82. https://doi.org/10.1134/S0012496610020031
[9] Medvedeva, E. V., Dmitrieva, V. G., Povarova, O. V., Limborskaya, S. A., Skvortsova, V. I., Myasoedov, N. F., & Dergunova, L. V. (2014). Effect of tripeptide Pro-Gly-Pro on rat brain transcriptome in focal ischemia. Molecular Biology, 48(2), 277–287. PMID: 25850296
[10] Zozulya, A. A., Kost, N. V., Sokolov, O. Y., Gabaeva, M. V., Grivennikov, I. A., Andreeva, L. N., Zolotarev, Y. A., Ivanov, S. V., Andryushchenko, A. V., Myasoedov, N. F., & Smulevich, A. B. (2001). The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bulletin of Experimental Biology and Medicine, 131(4), 315–317. https://doi.org/10.1023/A:1017979514274